[HTML][HTML] Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy

P Spirito, P Bellone, KM Harris… - … England Journal of …, 2000 - Mass Medical Soc
P Spirito, P Bellone, KM Harris, P Bernabň, P Bruzzi, BJ Maron
New England Journal of Medicine, 2000Mass Medical Soc
Background Sudden death is a possible consequence of hypertrophic cardiomyopathy.
Quantification of the risk of sudden death, however, remains imprecise for most patients with
this disease. Methods We assessed the relation between the magnitude of left ventricular
hypertrophy and mortality in 480 consecutive patients with hypertrophic cardiomyopathy.
The patients were categorized into five subgroups according to maximal wall thickness: 15
mm or less, 16 to 19 mm, 20 to 24 mm, 25 to 29 mm, and 30 mm or more. Their ages ranged …
Background
Sudden death is a possible consequence of hypertrophic cardiomyopathy. Quantification of the risk of sudden death, however, remains imprecise for most patients with this disease.
Methods
We assessed the relation between the magnitude of left ventricular hypertrophy and mortality in 480 consecutive patients with hypertrophic cardiomyopathy. The patients were categorized into five subgroups according to maximal wall thickness: 15 mm or less, 16 to 19 mm, 20 to 24 mm, 25 to 29 mm, and 30 mm or more. Their ages ranged from 1 to 89 years (median, 47).
Results
Over a mean follow-up period of 6.5 years, 65 of the 480 patients (14 percent) died: 23 suddenly, 15 of heart failure, and 27 of noncardiac causes or stroke. The risk of sudden death increased progressively and in direct relation to wall thickness (P=0.001), ranging from 0 per 1000 person-years (95 percent confidence interval, 0 to 14.4) for a wall thickness of 15 mm or less to 18.2 per 1000 person-years (95 percent confidence interval, 7.3 to 37.6) for a wall thickness of 30 mm or more and almost doubling from each wall-thickness subgroup to the next. The cumulative risk 20 years after the initial evaluation was close to zero for patients with a wall thickness of 19 mm or less but almost 40 percent for wall thicknesses of 30 mm or more. As compared with the other subgroups, patients with extreme hypertrophy were the youngest (mean age, 31 years), and most (41 of 43) had mild symptoms or no symptoms; of the 12 patients who were less than 18 years old at the initial evaluation, 5 died suddenly.
Conclusions
In hypertrophic cardiomyopathy, the magnitude of hypertrophy is directly related to the risk of sudden death and is a strong and independent predictor of prognosis. Young patients with extreme hypertrophy, even those with few or no symptoms, appear to be at substantial long-term risk and deserve consideration for interventions to prevent sudden death. The majority of patients with mild hypertrophy are at low risk and can be reassured regarding their prognosis.
The New England Journal Of Medicine